Arkema Shares Up 5.26% at Opening, Boosted by Q3 Earnings Release
Arkema announced its third-quarter 2025 results this morning. The company reported a 4.7% decrease in revenue at constant exchange rates, while its EBITDA fell by 23.8%. Facing reduced demand in the United States and Europe, the company also revised its targets for the current year, lowering its expected EBITDA to a range of 1.25 to 1.3 billion euros from a previous target of 1.3 to 1.4 billion euros.
Chemical Group's Stock Rises Amid Market Fluctuations
The chemical group's stock price increased by 5.26% this morning to 51.60 euros. This rise follows a tumultuous week, marked by a slight decline of 0.19% over seven days and a more significant correction of 13.78% over three months. Today's rebound is particularly noticeable as Arkema is recovering from an extremely difficult year, with a decline of 37.76% over the past twelve months. However, trading volume remains moderate, representing 0.08% of the capital, reflecting limited participation in the movement. The stock's progress also occurs in a context where the CAC 40 index is up by 0.19% at 7,980.08 points, highlighting that Arkema's rebound significantly outperforms the general market trend.
Technical Analysis Supports Potential Rebound
Technically, the stock finds support in the relative strength index positioned at 29, a level indicating an oversold condition that historically often precedes tactical rebounds. However, the price remains well below its 50-day moving average of 54.30 euros, indicating a general medium-term bearish trend. The MACD line, negative at -0.95, still lacks a clear buy signal, although the gap is gradually narrowing with the signal line positioned at -0.75. The stock maintains its support at 49.02 euros, providing a safety cushion before potential further pressures, while resistance is at 55.20 euros. With a beta of 0.29, Arkema shows a low correlation with broader market movements, which may attract investors seeking relative stability amid market turbulence.
